The Trump administration is currently considering implementing a five-year pilot program that would provide coverage for weight-loss drugs under Medicare and Medicaid, according to the Washington Post.

The report is based on documents from the Centers for Medicare and Medicaid Services that describe the proposal. 

The drugs under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and Mounjaro, the documents showed.